The estimated Net Worth of David M Reese is at least $20.4 Million dollars as of 16 February 2021. Mr. Reese owns over 2,300 units of AMGEN stock worth over $13,878,629 and over the last 6 years he sold AMGN stock worth over $0. In addition, he makes $6,537,920 as Executive Vice President - Research and Development at AMGEN.
David has made over 2 trades of the AMGEN stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,300 units of AMGN stock worth $125,787 on 16 February 2021.
The largest trade he's ever made was exercising 2,300 units of AMGEN stock on 16 February 2021 worth over $125,787. On average, David trades about 102 units every 9 days since 2018. As of 16 February 2021 he still owns at least 42,059 units of AMGEN stock.
You can see the complete history of Mr. Reese stock trades at the bottom of the page.
David M. Reese serves as Executive Vice President - Research and Development of the Company. Dr. Reese joined the Company in 2005 and has held leadership roles in development, medical sciences and discovery research. Dr. Reese was Senior Vice President, Translational Sciences and Oncology from 2017 to 2018 and Senior Vice President, Translational Sciences from 2015 to 2017. Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group from 2001 to 2003 and a cofounder, president and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, from 2003 to 2005. Dr. Reese previously served on the faculty at University of California, Los Angeles, and the University of California, San Francisco.
As the Executive Vice President - Research and Development of AMGEN, the total compensation of David Reese at AMGEN is $6,537,920. There are 3 executives at AMGEN getting paid more, with Robert Bradway having the highest compensation of $19,612,800.
David Reese is 57, he's been the Executive Vice President - Research and Development of AMGEN since 2018. There are 17 older and 8 younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
David's mailing address filed with the SEC is 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.
Over the last 21 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer, and Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
AMGEN executives and other stock owners filed with the SEC include: